Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments
This article was originally published in The Pink Sheet Daily
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.
You may also be interested in...
Amgen’s argument that continuing the Medicare new technology add-on payment for Blincyto would allow for more data to be collected failed to persuade US CMS.
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.